Effects of triazolam at three phases of the menstrual cycle

Journal of Clinical Psychopharmacology

Volumn 19, Issue 5, 1999, Pages 450-458

  Rukstalis, Margaret ^a,b   De Wit, Harriet ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; BENZODIAZEPINE DERIVATIVE; ESTRADIOL; PROGESTERONE; TRIAZOLAM;

ADULT; AROUSAL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FATIGUE; FEMALE; FOLLICULAR PHASE; HORMONE BLOOD LEVEL; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; MOOD; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OVULATION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF REPORT;

ADOLESCENT; ADULT; AFFECT; AREA UNDER CURVE; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; GABA MODULATORS; HALF-LIFE; HUMANS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; PROGESTERONE; PSYCHOMOTOR PERFORMANCE; TRIAZOLAM;

EID: 0032843928     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199910000-00009     Document Type: Article

References (46)

1. Merkatz R, Temple R, Sobel S, Reiden K, Dessler D. Women in clinical trials of new drugs: a change in Food & Drug Administration policy. N Engl J Med 1993;329:292-9.
2. Yonkers K, Kando J, Cole J, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medications. Am J Psychiatry 1992;149:587-95.
3. Yonkers K, Harrison W. Inclusion of women in psychopharmacologic trials. J Clin Psychopharmacol 1993;13:380-2.
4. Mellinger G, Balter M, Uhlenhuth E. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA 1984;251:375-9.
5. Mazza D, Dennerstein L, Ryan V. Psychotropic drugs use by women: current prevalence and associations. Med J Aust 1995;163:86-9.
6. Yen S, Jaffe R. Reproductive endocrinology physiology, pathophysiology and clinical management. Philadelphia: W.B. Saunders, 1991.
7. Abernethy D, Greenblatt D, Divoll M, Arendt R, Ochs H, Shader R. Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids. N Engl J Med 1982;306:791-2.
8. Roberts R, Desmond P, Wilkinson G, Schenker S. Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Clin Pharmacol Ther 1979;25:826-31.
9. Stoehr G, Kroboth P, Juhl R, Wender D, Phillips J, Smith R. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther 1984;36:683-90.
10. Jochemsen R, Graaff MVD, Boeijinga J, Breimer D. Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. Br J Clin Pharmacol 1982;13:319-24.
11. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther 1991;50:404-9.
12. Stern K, McClintock M. Biologic rhythms and individual variation: accurate measurements of menstrual cycle phase and the preovulatory LH surge. In: Jensvold M, Halbreich U, Hamilton J, eds. Psychopharmacology of women. Washington, DC: American Psychiatric Press, 1996:393-407.
13. Majewska M. Steroids and brain activity: essential dialogue between body and mind. Biochem Pharmacol 1987;36:3781-8.
14. McEwen B, Parsons B. Gonadal steroid action on the brain: neurochemistry and neuropharmacology. Ann Rev Pharmacol Toxicol 1982;22:555-98.
15. Majewska M, Harrison N, Schwartz R, Barker J, Paul S. Steroid hormone metabolites are barbiturate-like modulators of the GABAA receptor. Science 1986;232:1004-7.
16. McAuley J, Reynolds I, Kroboth F, Smith R, Kroboth P. Orally administered progesterone enhances sensitivity to triazolam in postmenopausal women. J Clin Psychopharmacol 1995;15:3-11.
17. Bertz R, Reynolds I, Kroboth P. Effect of neuroactive steroids on [3H] flumazenil binding to the GABAA receptor complex in vitro. Neuropharmacology 1995;34:1169-75.
18. Zorumski C, Isenberg K. Insights into the structure and function of GABAA-benzodiazepine receptors: ion channels and psychiatry. Am J Psychiatry 1991;148:162-73.
19. Wieland S, Lan N, Mirasedeghi S, Gee K. Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3 alpha-ol-20-one. Brain Res 1991;565:263-8.
20. Bitran D, Hilvers R, Kellogg C. Anxiolytic effects of 3 alpha-hydroxy-5 alpha-hydroxy-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res 1991;561:157-61.
21. Belelli D, Bolger M, Gee K. Anticonvulsant profile of the progesterone metabolite 5 alpha-pregnane-3 alpha-ol-20-one. Eur J Pharmacol 1989;166:325-9.
22. Kavaliers M, Wiebe J. Analgesic effects of the progesterone metabolite, 3 alpha-hydroxy-5 alpha-pregnan-20-one, and possible modes of action in mice. Brain Res 1987;1987:393-8.
23. Carl P, Hogskilde S, Nielsen J, Sorensen M, Lindholm M, Karlen B, Backstrom T. Pregnanolone emulsion. A preliminary pharmacokinetic and pharmacodynamic study of a new intravenous anesthetic agent. Anaesthesia 1990;45:189-97.
24. Grant K, Azarov A, Bowen C, Mirkis S, Purdy R. Ethanol-like discriminative stimulus effects of the neurosteroid 3 alpha-hydroxy-5 alpha-hydroxy-pregnan-20-one in female Macaco fascicularis monkeys. Psychopharmacology (Berl) 1996;124:340-6.
25. Grant K, Azarov A, Shively C, Purdy R. Discriminative stimulus effects of ethanol and 3 alpha-hydroxy-5 alpha-hydroxy-pregnan-20-one in relation to menstrual cycle in cynomolgus monkeys (Macaca fascicularis). Psychopharmacology (Berl) 1997;130: 59-68.
26. Arafat E, Hargrove J, Maxson W, Disiderio D, Wentz A, Andersen R. Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. Am J Obstet Gynecol 1988;159:1203-9.
27. Freeman E, Purdy R, Coutifaris C, Rickels K, Paul S. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 1993;58: 478-84.
28. Kroboth P, Smith R, Stoehr G, Juhl R. Pharmacodynamic evaluation of benzodiazepine-oral contraceptive interaction. Clin Pharmacol Ther 1985;38:525-32.
29. Joels M. Steroid hormones and excitability in the mammalian brain. Front Neuroendocrinol 1997;18:2-48.
30. Leibenluft E, Fiero P, Rubinow D. Effects of the menstrual cycle on dependent variables in mood disorder research. Arch Gen Psychiatry 1994;51:761-81.
31. de Wit H, Rukstalis M. Acute effects of triazolam in women: relationships with progesterone, estradiol and allopregnanolone. Psychopharmacology (Berl) 1997;130:69-78.
32. Paul S, Purdy R. Neuroactive steroids. FASEB 1992;6:2311-22.
33. Sethy V, Harris D. Determination of biological activity of alprazolam, triazolam and their metabolites. J Pharm Pharmacol 1982; 34:115-6.
34. Roache J, Griffiths R. Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability. J Pharmacol Exp Ther 1985;234:120-33.
35. Derogatis L. SCL-90-R Manual-II. Towson, MD: Clinical Psychometric Research, 1983.
36. Batista M, Carledge T, Zellmer A, Nieman L, Merriam G, Loriaux D. Evidence for a critical role of progesterone in the regulation of the midcycle gonadotropin surge and ovulation. J Clin Endocrinol Metab 1992;74:565-70.
37. Rosenfleld R, Barnes R, Ehrmann D. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1994;79:1686-92.
38. Purdy R, Moore P, Ruo P, Hagino N, Yamaguchi T, Schmidt P, Rubinow D, Morrow A, Paul S. Radioimmunoassay of 3 alpha-hydroxy-5 alpha-pregnane-20-one in rat and human plasma. Steroids 1990;55:290-6.
39. Greenblatt D, Divoll M, Moschitto L, Shader R. Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam. J Chromatogr 1981;225:202-7.
40. McNair D, Lorr M, Droppleman D. Profile of mood states. San Diego, CA: Educational and Industrial Testing Service, 1971.
41. Folstein M, Luria R. Reliability, validity and clinical applications of the visual analogue mood scale. Psychol Med 1973;3:479-86.
42. Johanson C, Uhlenhuth E. Drug preference and mood in humans: d-amphetamine. Psychopharmacology (Berl) 1980;71:275-9.
43. Weschler D. The measure and appraisal of adult intelligence. Baltimore: Williams & Wilkins, 1958.
44. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980;10:189-209.
45. Hindmarch I, Kerr J, Sherwood N. The effects of alcohol and other drugs on psychomotor performance and cognitive function. Alcohol Alcohol 1991;26:71-9.
46. de Wit H, Griffiths R. Methods of assessing abuse liability of sedatives in humans. Drug Alcohol Depend 1991;28:83-111.